Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurogene Inc (NGNE)

Neurogene Inc (NGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 261,626
  • Shares Outstanding, K 15,490
  • Annual Sales, $ 930 K
  • Annual Income, $ -75,140 K
  • EBIT $ -97 M
  • EBITDA $ -96 M
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.95

Options Overview Details

View History
  • Implied Volatility 136.63% (-41.08%)
  • Historical Volatility 73.63%
  • IV Percentile 64%
  • IV Rank 29.01%
  • IV High 233.99% on 04/07/25
  • IV Low 96.85% on 11/26/25
  • Expected Move (DTE 8) 0.98 (5.79%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 1.10
  • Today's Open Interest 1,120
  • Open Int (30-Day) 800
  • Expected Range 15.91 to 17.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.20
  • Number of Estimates 6
  • High Estimate -1.01
  • Low Estimate -1.59
  • Prior Year -0.99
  • Growth Rate Est. (year over year) -21.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.93 +6.03%
on 02/05/26
20.44 -17.37%
on 01/28/26
-1.03 (-5.75%)
since 01/09/26
3-Month
15.93 +6.03%
on 02/05/26
32.02 -47.25%
on 11/12/25
-13.98 (-45.29%)
since 11/11/25
52-Week
6.88 +145.49%
on 04/08/25
37.27 -54.68%
on 10/16/25
-0.90 (-5.06%)
since 02/11/25

Most Recent Stories

More News
Neurogene to Participate in Upcoming Investor Conferences

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management...

NGNE : 16.89 (-0.65%)
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 16.89 (-0.65%)
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

Dosed multiple participants in Emboldenâ„¢ registrational trial in fourth quarter of 2025 Completion of dosing in Embolden expected in second quarter of 2026 ...

NGNE : 16.89 (-0.65%)
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management...

NGNE : 16.89 (-0.65%)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 16.89 (-0.65%)
Neurogene: Q3 Earnings Snapshot

Neurogene: Q3 Earnings Snapshot

NGNE : 16.89 (-0.65%)
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

Reported positive interim data from NGN-401 Phase 1/2 gene therapy trial for Rett syndrome demonstrating multidomain, durable gains, with 35 total developmental milestones/skills acquired...

NGNE : 16.89 (-0.65%)
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

Multidomain, durable gains with continued skill acquisition over time All 8 participants showed functional gains across spectrum of disease severity ...

NGNE : 16.89 (-0.65%)
Neurogene Announces First Participant Dosed in Emboldenâ„¢ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Single trial to support future BLA submission for NGN-401 in patients ages ≥ 3 years Rapid trial execution underway with 12 of 13 clinical sites initiated ...

NGNE : 16.89 (-0.65%)
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 16.89 (-0.65%)

Business Summary

Neurogene Inc. is a clinical-stage company which bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene Inc., formerly known as Neoleukin Therapeutics Inc., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 18.09
2nd Resistance Point 17.58
1st Resistance Point 17.23
Last Price 16.89
1st Support Level 16.37
2nd Support Level 15.86
3rd Support Level 15.51

See More

52-Week High 37.27
Fibonacci 61.8% 25.66
Fibonacci 50% 22.07
Fibonacci 38.2% 18.49
Last Price 16.89
52-Week Low 6.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar